Literature DB >> 15062194

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.

Gustav Paumgartner1, Ulrich Beuers.   

Abstract

Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases: (1) protection of injured cholangiocytes against toxic effects of bile acids, (2) stimulation of impaired biliary secretion, (3) stimulation of detoxification of hydrophobic bile acids, and (4) inhibition of apoptosis of hepatocytes. Through one or more of these mechanisms, UDCA slows the progression of primary biliary cirrhosis and improves a number of other cholestatic disorders.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15062194     DOI： 10.1016/S1089-3261(03)00135-1

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  40 in total

1.  High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

Authors:  M H Imam; E Sinakos; A A Gossard; K V Kowdley; V A C Luketic; M Edwyn Harrison; T McCashland; A S Befeler; D Harnois; R Jorgensen; J Petz; J Keach; A C DeCook; F Enders; K D Lindor
Journal:  Aliment Pharmacol Ther       Date:  2011-09-29       Impact factor: 8.171

2.  Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid.

Authors:  Dongling Dai; Philippa B Mills; Emma Footitt; Paul Gissen; Patricia McClean; Jens Stahlschmidt; Isabelle Coupry; Julie Lavie; Fanny Mochel; Cyril Goizet; Tatsuki Mizuochi; Akihiko Kimura; Hiroshi Nittono; Karin Schwarz; Peter J Crick; Yuqin Wang; William J Griffiths; Peter T Clayton
Journal:  J Inherit Metab Dis       Date:  2014-09       Impact factor: 4.982

Review 3.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 4.  Expression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis.

Authors:  Anabel Brandoni; María Herminia Hazelhoff; Romina Paula Bulacio; Adriana Mónica Torres
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

5.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

Review 6.  Molecular mechanisms of cholestasis.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Wien Med Wochenschr       Date:  2006-07

Review 7.  Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Authors:  Michael Trauner; Peter Fickert; Emina Halilbasic; Tarek Moustafa
Journal:  Wien Med Wochenschr       Date:  2008

8.  Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase.

Authors:  Peter I Mackenzie; Anne Rogers; Joanna Treloar; Bo R Jorgensen; John O Miners; Robyn Meech
Journal:  J Biol Chem       Date:  2008-11-03       Impact factor: 5.157

9.  Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease.

Authors:  Carsten Gnewuch; Gerhard Liebisch; Thomas Langmann; Benjamin Dieplinger; Thomas Mueller; Meinhard Haltmayer; Hans Dieplinger; Alexandra Zahn; Wolfgang Stremmel; Gerhard Rogler; Gerd Schmitz
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.